{"groups":[{"description":"* Pomalidomide: once daily oral (PO) dosing on days 1-21, every 28 days\n* Bendamustine: once intravenous (IV) dosing on day 1, every 28 days\n* Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22 every 28 days\n\nAfter 6 cycles of treatment, dexamethasone may be decreased to 20mg. After total 12 cycles of treatment, subjects will proceed to the maintenance phase until time of progression.\n\nStudy treatment will be administered starting at Cohort 1 for up to four sequential cohorts, with 3-6 patients in each cohort.","id":"FG000","title":"Cohort 1: 120mg Bendamustine + 3mg Pomalidomide"},{"description":"* Pomalidomide: once daily oral (PO) dosing on days 1-21, every 28 days\n* Bendamustine: once intravenous (IV) dosing on day 1, every 28 days\n* Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22 every 28 days\n\nAfter 6 cycles of treatment, dexamethasone may be decreased to 20mg. After total 12 cycles of treatment, subjects will proceed to the maintenance phase until time of progression.\n\nStudy treatment will be administered starting at Cohort 1 for up to four sequential cohorts, with 3-6 patients in each cohort.","id":"FG001","title":"Cohort 2: 120mg Bendamustine + 4mg Pomalidomide"},{"description":"* Pomalidomide: once daily oral (PO) dosing on days 1-21, every 28 days\n* Bendamustine: once intravenous (IV) dosing on day 1, every 28 days\n* Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22 every 28 days\n\nAfter 6 cycles of treatment, dexamethasone may be decreased to 20mg. After total 12 cycles of treatment, subjects will proceed to the maintenance phase until time of progression.\n\nStudy treatment will be administered at the Maximum Tolerated Dose.","id":"FG002","title":"Expansion: 120mg Bendamustine + 3mg Pomalidomide"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}],"type":"Lack of Efficacy"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"30"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"26"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"4"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Nine patients were consented to the study for cohort 1, however, 3 were screen failures. Seven patients were consented to the study for cohort 2, however, 5 were screen failures. Forty patients were consented to the study for the expansion phase, however, 10 were screen failures.","recruitmentDetails":"Recruitment began in January 2013. Dose escalation ended in November, 2013. Expansion enrollment began in December, 2013 and ended in September 2016. Patients were recruited from the Bone Marrow Transplant Clinic and Hematologic Malignancies Clinic at Duke University Medical Center."}